File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.jconrel.2019.10.035
- Scopus: eid_2-s2.0-85074054010
- PMID: 31644935
- WOS: WOS:000499615300005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Rational particle design to overcome pulmonary barriers for obstructive lung diseases therapy
Title | Rational particle design to overcome pulmonary barriers for obstructive lung diseases therapy |
---|---|
Authors | |
Keywords | Lung barriers Pulmonary delivery Rational particle design Obstructive lung diseases |
Issue Date | 2019 |
Publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jconrel |
Citation | Journal of Controlled Release, 2019, v. 314, p. 48-61 How to Cite? |
Abstract | Pulmonary delivery of active drugs has been applied for the treatment of obstructive lung diseases, including asthma, chronic obstructive pulmonary disease and cystic fibrosis, for several decades and has achieved progress in symptom management by bronchodilator inhalation. However, substantial progress in anti-inflammation, prevention of airway remodeling and disease progression is limited, since the majority of the formulation strategies focus only on particle deposition, which is insufficient for pulmonary delivery of the drugs. The lack of knowledge on lung absorption barriers in obstructive lung diseases and on pathogenesis impedes the development of functional formulations by rational design. In this review, we describe the physiological structure and biological functions of the barriers in various regions of the lung, review the pathogenesis and functional changes of barriers in obstructive lung diseases, and examine the interaction of these barriers with particles to influence drug delivery efficiency. Subsequently, we review rational particle design for overcoming lung barriers based on excipients selection, particle size and surface properties, release properties and targeting ability. Additionally, useful particle fabrication strategies and commonly used drug carriers for pulmonary delivery in obstructive lung diseases are proposed in this article. |
Persistent Identifier | http://hdl.handle.net/10722/286238 |
ISSN | 2023 Impact Factor: 10.5 2023 SCImago Journal Rankings: 2.157 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | He, Y | - |
dc.contributor.author | Liang, Y | - |
dc.contributor.author | Han, R | - |
dc.contributor.author | Lu, WL | - |
dc.contributor.author | Mak, JCW | - |
dc.contributor.author | Zheng, Y | - |
dc.date.accessioned | 2020-08-31T07:01:07Z | - |
dc.date.available | 2020-08-31T07:01:07Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Journal of Controlled Release, 2019, v. 314, p. 48-61 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | http://hdl.handle.net/10722/286238 | - |
dc.description.abstract | Pulmonary delivery of active drugs has been applied for the treatment of obstructive lung diseases, including asthma, chronic obstructive pulmonary disease and cystic fibrosis, for several decades and has achieved progress in symptom management by bronchodilator inhalation. However, substantial progress in anti-inflammation, prevention of airway remodeling and disease progression is limited, since the majority of the formulation strategies focus only on particle deposition, which is insufficient for pulmonary delivery of the drugs. The lack of knowledge on lung absorption barriers in obstructive lung diseases and on pathogenesis impedes the development of functional formulations by rational design. In this review, we describe the physiological structure and biological functions of the barriers in various regions of the lung, review the pathogenesis and functional changes of barriers in obstructive lung diseases, and examine the interaction of these barriers with particles to influence drug delivery efficiency. Subsequently, we review rational particle design for overcoming lung barriers based on excipients selection, particle size and surface properties, release properties and targeting ability. Additionally, useful particle fabrication strategies and commonly used drug carriers for pulmonary delivery in obstructive lung diseases are proposed in this article. | - |
dc.language | eng | - |
dc.publisher | Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jconrel | - |
dc.relation.ispartof | Journal of Controlled Release | - |
dc.subject | Lung barriers | - |
dc.subject | Pulmonary delivery | - |
dc.subject | Rational particle design | - |
dc.subject | Obstructive lung diseases | - |
dc.title | Rational particle design to overcome pulmonary barriers for obstructive lung diseases therapy | - |
dc.type | Article | - |
dc.identifier.email | Liang, Y: winniell@hku.hk | - |
dc.identifier.email | Mak, JCW: judithmak@hku.hk | - |
dc.identifier.authority | Mak, JCW=rp00352 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.jconrel.2019.10.035 | - |
dc.identifier.pmid | 31644935 | - |
dc.identifier.scopus | eid_2-s2.0-85074054010 | - |
dc.identifier.hkuros | 313199 | - |
dc.identifier.volume | 314 | - |
dc.identifier.spage | 48 | - |
dc.identifier.epage | 61 | - |
dc.identifier.isi | WOS:000499615300005 | - |
dc.publisher.place | Netherlands | - |
dc.identifier.issnl | 0168-3659 | - |